51³ΙΘΛΆ―Βώ

Meeting Coverage

WCLC

World Conference on Lung Cancer

Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

WCLC over a photo of San Diego Conference Center in San Diego, CA.

Latest WCLC Meeting Coverage

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

However, plinabulin plus docetaxel still "not ready for prime time," expert says

September 10, 2024
MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

September 10, 2024
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

September 9, 2024
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

September 9, 2024
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy

September 9, 2024
IMRT Best for Locally Advanced NSCLC, Study Suggests

Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT

September 13, 2023
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC

Confirmed responses reached 29.8% in heavily pretreated patients

September 13, 2023
Study Questions Use of Aggressive Surgery in Early Mesothelioma

Randomized data suggest surgery increases risk of death by 28% over first 42 months

September 12, 2023
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer

Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone

September 12, 2023
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC

Median overall survival reached 19.3 months in Chinese trial

September 11, 2023
'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo

Long-term follow-up shows continued survival benefit as first-line treatment

August 11, 2022
Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutations

Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo

August 10, 2022
Survey: 77% of Women With Lung Cancer Report Sexual Dysfunction

Results show need to integrate sexual health into care, researcher says

August 9, 2022
Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC

Phase II trial supports neoadjuvant nivolumab plus chemotherapy

August 9, 2022